Mode
Text Size
Log in / Sign up
Phase 4 N=248 Randomized Quadruple-blind Treatment

Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso

Child Development

Enrolled (actual)
248
Serious AEs
0.0%
Results posted
Mar 2023
Primary outcome: Primary: Simpson's Index of Diversity (Alpha Diversity) in Intestinal Microbiome — 10.2; 8.8; 9.7; 9.6 Index score

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Azithromycin (Drug); Amoxicillin (Drug); Cotrimoxazole (Drug); Placebo (Drug)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
University of California, San Francisco
Primary completion
Sep 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Simpson's Index of Diversity (Alpha Diversity) in Intestinal Microbiome
10.2; 8.8; 9.7; 9.6; 8.3; 6.6
SECONDARY
Simpson's Index of Diversity (Alpha Diversity) in Microbiome
SECONDARY
Weight-for-height Z-score
-0.24; -0.71; -0.27; -0.52; -0.17; -0.49
SECONDARY
Height-for-age Z-score
-0.80; -0.92; -0.69; -0.73; -1.16; -1.38
SECONDARY
Weight-for-age Z-score
-0.60; -1.01; -0.58; -0.78; -0.78; -1.12
SECONDARY
Mid-upper Arm Circumference
15.01; 14.53; 15.49; 14.90; 15.15; 14.83
SECONDARY
Shannon's Index of Diversity (Alpha Diversity) in Intestinal Microbiome
16.6; 14.6; 15.6; 15.4; 13.9; 11.0
SECONDARY
Shannon's Index of Diversity (Alpha Diversity) in Nasopharyngeal Microbiome
SECONDARY
L1-norm Distance on Bacterial Reads (Intestinal)
16.6; 14.6; 15.6; 15.4; 13.9; 11.0
SECONDARY
L1-norm Distance on Bacterial Reads (Nasopharyngeal)
SECONDARY
L2-norm Distance on Bacterial Reads (Intestinal)
10.2; 8.8; 9.7; 9.6; 8.3; 6.6
SECONDARY
L2-norm Distance on Bacterial Reads (Nasopharyngeal)
SECONDARY
Number of Participants With Macrolide Resistance Genes
12; 9
SECONDARY
Alpha Diversity in the Intestinal Microbiome

Summary

The use of antibiotics has saved millions of human lives, however consumption of antibiotics can select for antibiotic resistant organisms and may lead to changes in commensal microbiome. This study is designed to estimate the effect of antibiotic consumption on microbiome in a rural region of rural Burkina Faso. Changes in the intestinal and nasopharyngeal microbiome and resistome following a short course of antibiotics will be measured.

Eligibility Criteria

Inclusion Criteria

  • Households will be eligible for inclusion in the study if they have 2 or more children aged 6 months to 59 months currently residing in the household. Children from the household will be eligible if they are 6-59 months of age and are not currently receiving antibiotic treatment

Exclusion Criteria

  • Children who are allergic to any of the study antibiotics will be excluded. Individuals aged under 6 months and 5 years or older will be excluded. Children already receiving antibiotics for an ongoing disease will be excluded.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03187834). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search